Postdoctoral researcher specializing in cancer biology, pursuing an understanding of tumor molecular mechanisms to reveal novel clinical therapies for cancer since 2005.
As a postdoctoral researcher at the Cancer Epigenetics Group, I have been working on cancer epigenetics and epitranscriptomics since 2017.
My main goal is to contribute to cancer research providing new and detailed insight into the biology and molecular mechanisms of the tumor for overcoming cancer drug resistance as well as providing novel and precise epigenetic and epitranscriptomic biomarkers as prognostic indicators, predictive factors for therapy response, and therapeutic drug targets in oncology.
Currently, I am focused on the understanding of the role of an RNA-modifying enzyme and its RNA modifications on novel RNA target transcripts to provide a better insight on cancer epitranscriptomics and improve cancer treatment outcomes in patients.
Also, my devotion to scientific exchange brought me to the Accelerating Science and Publication in Biology organization (ASAPbio), inspired by their initiatives and actions and for being a vibrant, collaborative, and supportive community of researchers. I have been actively involved in the ASAPbio organization as an ASAPbio ambassador since April 2016. I support preprints for the life sciences to fulfill the principles of ASAPbio that are transparency, research integrity, equity, and reliable timing of disclosure.
My years as a Ph.D. student at the Vall d'Hebron Research Institute (VHIR) in Barcelona and as a postdoctoral researcher at the University of California, San Francisco (UCSF) in the USA have been dynamic, working in translational research and together across disciplines and departments.
Between January 2012 and January 2017, as a postdoctoral researcher at UCSF Helen Diller Family Comprehensive Cancer Center, I contributed to the discoveries of (1) a cytoplasmic long noncoding RNA (lncRNA) and its emerging role in modulating the oncogenic signaling pathway of MAPK cascade, a future promising strategy for combating one of the multiple drug resistance mechanisms in melanoma; (2) identification and characterization of new kinase fusions in spitz tumors and spitzoid melanomas; (3) the missing pieces in the UV-induced DNA damage response pathway, the new role of the serine-threonine kinase LKB1 as a DNA damage sensor and as a prognostic risk factor of UV-induced skin cancer; and (4) collaborative research projects such as the identification and understanding of the molecular mechanisms of resistance to targeted therapeutics in hematopoietic malignancies (mechanisms of drug resistance in c-KIT) and the knowledge of the impact of inhibiting MEK/ERK and PI3K/AKT signaling pathways in melanoma.